Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Anavex Life Sciences Corp.NASDAQ: AVXL

Cash & Equivalents · Q1 FY2026 · quarter ended Dec 2025

Cash & equivalents rises 9.1% from a year ago

Cash & equivalents stood at $131.75M at the end of Q1 FY2026, up 9.1% from a year earlier and up 28.4% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Cash & equivalents amounted to 99.1% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +9.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$131.75M+28.4% QoQ
Last fiscal yearSep 2025
$102.58M-22.4% YoY
Year agoDec 2024
$120.78M+9.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.1%——
1 year-22.4%——
3-year CAGR-11.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
102.58M USD
Year-over-year change
-22.4%
4-year CAGR
-9.4%

Cash & Equivalents vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +9.1% is the 3rd highest of 10, against a peer median of -27.5%.
  • Cash & equivalents amounts to 99.1% of total assets for AVXL, versus a peer median of 13.5%.
AVXL Competitors
Cash & Equivalents for AVXL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$298.49M USD+9.9%+103.8%74.6%
MBXMBX Biosciences, Inc. Common StockSep 2026$161.69M USD-27.5%+46.0%32.3%
AVXLAnavex Life Sciences Corp.Dec 2025$131.75M USD+9.1%-11.7%99.1%
ERASErasca, Inc.Sep 2026$118.96M USD+69.4%-36.2%11.9%
VALNValneva SEMar 2026€105.37M EUR-31.1%-27.6%28.3%
ARVNArvinas, Inc.Mar 2026$87.3M USD+7.8%+20.7%13.5%
MGTXMeiraGTx Holdings plcMar 2026$71.54M USD+7.5%-17.1%29.2%
CTMXCytomX Therapeutics, Inc.Mar 2026$28.83M USD-39.4%-59.7%8.0%
RGNXREGENXBIO Inc.Mar 2026$15.23M USD-88.3%-29.2%4.5%
ABSIAbsci CorporationMar 2026$8.63M USD-81.6%-30.6%4.4%
Peer median (excluding AVXL) —-27.5%-27.6%13.5%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents152.11M149.16M151.02M132.19M102.58M
Short-term Investments00000
Net Receivables9.14M3.19M2.71M2.45M809K
Inventory16.37K0000
Other Current Assets(16.37K)162653K931K429K
Total Current Assets161.62M152.7M154.39M135.57M103.82M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets16.37K3.55B3.36M00
Total Non-current Assets16.37K3.55B3.36M00
Total Assets161.62M152.7M154.39M135.57M103.82M
Account Payables4.74M3.82M4.32M9.63M4.25M
Short-term Debt00000
Tax Payables00000
Deferred Revenue443.83K443.83K917K842K805K
Other Current Liabilities0(47)1.36M1.53M1.56M
Total Current Liabilities10.8M10.21M12.53M15.3M8.95M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities10.8M10.21M12.53M15.3M8.95M
Common Stock75.92K77.94K82K85K87K
Retained Earnings(197.59M)(245.56M)(293.07M)(336.07M)(382.45M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity150.82M142.49M141.85M120.26M94.87M
Total Debt00000
Net Debt(152.11M)(149.16M)(151.02M)(132.19M)(102.58M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.